[HTML] nejm.org

[HTML][HTML] Bamlanivimab plus etesevimab in mild or moderate Covid-19

M Dougan, A Nirula, M Azizad… - … England Journal of …, 2021 - Mass Medical Soc
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …
被引用次数：665 相关文章

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M Dougan, A Nirula, M Azizad… - The New England …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Bamlanivimab plus etesevimab in mild or moderate COVID-19.

M Dougan, A Nirula, M Azizad, B Mocherla, RL Gottlieb… - 2021 - cabidigitallibrary.org
BACKGROUND: Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …
[HTML] nih.gov

[HTML][HTML] Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M Dougan, A Nirula, M Azizad, B Mocherla… - The New England … - ncbi.nlm.nih.gov
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.

M Dougan, A Nirula, M Azizad, B Mocherla… - The New England …, 2021 - europepmc.org
Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M Dougan, A Nirula, M Azizad, B Mocherla… - New England Journal …, 2021 - cir.nii.ac.jp
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …